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Abstract
Background: A key aspect of the design of randomised controlled trials (RCTs) is determining the sample size. It is
important that the trial sample size is appropriately calculated. The required sample size will differ by clinical area, for
instance, due to the prevalence of the condition and the choice of primary outcome. Additionally, it will depend upon
the choice of target difference assumed in the calculation. Focussing upon the hip and knee osteoarthritis population,
this study aims to systematically review how the trial size was determined for trials of osteoarthritis, on what basis, and
how well these aspects are reported.
Methods: Several electronic databases (Medline, Cochrane library, CINAHL, EMBASE, PsycINFO, PEDro and AMED) will
be searched to identify articles on RCTs of hip and knee osteoarthritis published in 2016. Articles will be screened for
eligibility and data extracted independently by two reviewers. Data will be extracted on study characteristics (design,
population, intervention and control treatments), primary outcome, chosen sample size and justification, parameters
used to calculate the sample size (including treatment effect in control arm, level of variability in primary outcome, loss
to follow-up rates). Data will be summarised across the studies using appropriate summary statistics (e.g. n and %, median
and interquartile range). The proportion of studies which report each key component of the sample size calculation will
be presented. The reproducibility of the sample size calculation will be tested.
Discussion: The findings of this systematic review will summarise the current practice for sample size calculation in trials
of hip and knee osteoarthritis. It will also provide evidence on the completeness of the reporting of the sample size
calculation, reproducibility of the chosen sample size and the basis for the values used in the calculation.
Trial registration: As this review was not eligible to be registered on PROSPERO, the summary information was
uploaded to Figshare to make it publicly accessible in order to avoid unnecessary duplication amongst other benefits
(https://doi.org/10.6084/m9.figshare.5009027.v1); Registered January 17, 2017.
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Background
The sample size and target difference of a clinical trial is
a key feature that impacts on how the trial is designed
and conducted [1]. There are multiple factors which
contribute to the determination of the required sample
size with choice of target difference arguably the most
important [2, 3]. It is recognised that an overly large
sample size is undesirable as it increases the costs of the
trial and likely delays dissemination of the findings [2].
Too large a sample size is also unethical as it may result
in additional participants receiving a treatment when
there is already sufficient evidence to show that it is
inferior to an alternative [4]. Conversely, too small a
sample size also poses ethical issues as it will result in a
study lacking sufficient power to detect a clinically im-
portant treatment effect [5, 6].
Many studies have found that sample sizes are often
inadequately reported and based on inaccurate assump-
tions [7, 8]. Discrepancies in the assumptions for
parameters in sample size calculations can impact on
power [9, 10]. In particular, for continuous outcomes,
underestimation of the standard deviation can lead to
underpowered studies. Tavernier and Giraudeau hypothe-
sised that this mis-specification may be due to the impre-
cision and more homogeneous populations of pilot
studies often used to estimate the parameter [9].
OARSI (Osteoarthritis Research Society International)
recently published recommendations to use realistic and
clinically important effect sizes when calculating the
sample size for an osteoarthritis trial, suggesting that
previously some trials have not done so [11]. Keen et al.
found that rheumatology trials published in 2001–2002
were often underpowered and sample size calculations
were poorly reported [12]. Since then, there have been
considerable efforts to improve reporting of randomised
trials; for example, the Consolidated Standards of
Reporting Trials (CONSORT) Statement includes an
item to report how the ‘sample size was determined’
[13]. However, it is unclear how investigators currently
determine and report the sample size for trials of hip
and knee osteoarthritis.
Aim and objectives
The primary objective is to summarise the method-
ology used (including the assumptions made and
justifications provided) to determine the sample size
calculation for randomised trials of hip and knee
osteoarthritis.
The secondary objectives are to assess the reporting
and reproducibility of the sample size calculation.
Methods
The PRISMA-P Checklist for this review protocol is
available as Additional file 1.
Inclusion criteria
Studies will be eligible for inclusion if they are rando-
mised controlled trials of hip and/or knee osteoarthritis
with two treatment arms (one intervention and one
comparator) published in 2016. Inclusion will not be
restricted by study outcomes, intervention or control
treatments.
Exclusion criteria
Articles on non-randomised studies will be excluded,
including case-control or cross-sectional studies. Quasi-
randomised studies or studies which do not state that
the allocation was randomised will be excluded. Factorial
design and cross-over trials will be excluded. Trials with
more than two arms will be excluded.
Pilot studies will be excluded, as will studies which refer
to themselves as ‘feasibility’, ‘proof of concept’ or ‘explora-
tory’ studies. Studies which intend to use results to inform
future definitive phase III trials will not be included.
Studies which do not consider treatment evaluation (e.g.
compare different screening methods) will be excluded.
Studies on the prevention of osteoarthritis or trials
with mixed populations will be excluded; for example, a
combination of rheumatoid arthritis and osteoarthritis.
Trials of, for example, total knee arthroplasty will only
be eligible if it is clearly stated that all participants had
knee osteoarthritis.
Non-English language articles will be excluded as this
review focusses on study reporting.
Articles will be excluded if they are conference ab-
stracts or study protocols. Only the primary report of a
trial will be eligible; separate publications for secondary
analyses will be excluded, including long-term follow-up
or subgroup analyses.
Identification of studies
Articles reporting the results of clinical trials will be
identified using electronic searches of databases includ-
ing Medline, Cochrane Central Register of Controlled
Trials (CENTRAL), CINAHL, EMBASE, PsycINFO,
PEDro and AMED. An example search strategy is given
in Additional file 2.
A preliminary search to inform the search strategy in-
dicated that this would lead to around 100 included
studies, which was considered to be sufficiently large for
a methodological review of this kind [14–16].
Selection of studies
All search results will be combined and duplicates will be
removed. Titles and abstracts will be screened
independently by two reviewers. Following this, full texts
for the records considered to be potentially included will
be obtained and also screened independently by two re-
searchers. Any disagreements will be resolved through
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discussion between the two reviewers assessing the
papers, with involvement of a further reviewer where
necessary.
Data extraction and management
Data will be extracted using a standardised form. The
data-extraction form will be piloted to ensure that all
relevant information is recorded and to allow refinement
prior to formal use. The form will then be enhanced by
adding and clarifying items to extract. Data extraction
will be performed by a second reviewer on a sample of
included studies (at least 20%) in order to check accur-
acy. Relevant data will be extracted from the study
protocol where this is cited in the main trial results
publication; where there are conflicts between the infor-
mation in the protocol and main publication, informa-
tion from the main publication will be used.
The following information will be extracted from each
article when reported:
 Article: Country
 Design: Study design (e.g. superiority, non-
inferiority)
 Population: Condition (including how osteoarthritis
was defined), setting, eligibility criteria (in particular
age, gender, and disease severity).
 Treatment: Intervention, comparator.
 Outcome: Primary outcome measure(s)
 Sample size details: Statistical approach
(conventional, other), chosen sample size, method
for calculation, values used and justification (e.g. effect
size, target difference, standard deviation, adjustment
for loss to follow-up, sidedness, significance level,
power), whether sample size could be replicated,
whether sample size re-estimation was planned (e.g.
using interim analysis), whether sensitivity analysis
was conducted to examine impact of assumptions on
sample size. Note: Post-hoc sample size calculations
will not be considered.
 Follow-up: Number of participants randomised, number
lost to follow-up, whether compliance was measured.
Data synthesis
Data will be summarised across the studies, including
the general characteristics of the included studies using
appropriate summary statistics (e.g. n and %, median
and interquartile range (IQR)).
The proportion of studies that justify the sample size
and target difference, and which report each component
of the sample size calculation will be calculated.
The target difference expressed as a standardised effect
size (e.g. Cohen’s d for continuous outcome) will be pre-
sented graphically to compare across the studies and,
where there are a sufficient number of studies, within
conditions (i.e. considering hip osteoarthritis and knee
osteoarthritis separately) [17].
Sample size replication
Using the reported values, an attempt will be made to
replicate the sample size calculation. It will be assumed
that 80% power and 5% two-sided significance level were
used unless otherwise stated and that a conventional
(Neyman-Pearson) approach to the sample size calcula-
tion has been adopted [1]. The sample size calculation
will be replicated using statistical software such as the
‘power twomeans’ command in STATA IC 14 [18].
When comparing the replicated to stated sample size,
the ratio of replicated/reported values will be calculated.
Ratios will be presented in a box plot [19]. The proportion
of studies where the ratio is ≥ 1.1 or ≤ 0.9, and ≥ 1.3 or ≤
0.7 (i.e. out by at least 10% or 30%) will be calculated.
Subgroup analysis
Subgroup analysis will be used to explore the associa-
tions between study-level characteristics and key aspects
of the sample size calculation: (1) observed sample size
(number of participants randomised), (2) whether the
sample size calculation was fully specified and (3) replic-
ability. Data will be summarised within subgroups and
presented using box plots (median, interquartile range
(IQR) and range).
For subgroup comparisons, the following aspects will
be compared:
(1)Type of intervention: surgical vs non-surgical trials
(2)Centres: single vs multi-centre
(3)Funding: industry-funded (all or in part) vs no industry
funding (or not reported)
(4)Comparator: placebo/waitlist vs active control
If sufficient studies are reflected across the respective
subgroups, we will formally compare groups: (1) sample
size will be compared between subgroups using the me-
dian difference and 95% confidence interval. Absolute
risk differences with 95% confidence intervals will be
used to compare between subgroups for (2) reporting of
a sample size calculation, (3) reporting of core sample
size components and (4) the replicated sample size
being > 10% larger than the reported sample size.
Formal subgroup comparisons will only be conducted
where a sufficient number of studies are present within
each group. A two-sided significance level of 0.05 will be
used. As the subgroup analysis is exploratory, no adjust-
ment will be made for multiple testing.
Discussion
This review will examine the current practice for sample
size calculation in randomised trials of hip and knee
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osteoarthritis, which will include the target difference that
studies are designed to detect, the chosen sample size and
justification of key inputs. It will also provide evidence on
the completeness of the reporting of the sample size cal-
culation and the accuracy of the sample size calculation
(i.e. whether the calculation was reproducible). This sys-
tematic review will also provide insight into the number
of randomised trials being conducted on hip and knee
osteoarthritis and the variety of interventions being evalu-
ated. Focussing on a specific clinical area will permit a
more detailed assessment of the methodology within a
more homogeneous sample of trials.
Subgroup analysis will explore whether the sample size
used and reporting of the sample size calculation differ
based on type of intervention, number of centres, fund-
ing source and comparator. Surgical and non-surgical
studies will be compared since several studies have
highlighted the complexities of surgical trials and have
highlighted their poor methodological quality and
reporting [20–22]. Studies have also suggested that
multi-centre trials may have higher methodological qual-
ity than single-centre trials [20, 23, 24]. The effect of
funding source will be examined since previous reviews
have shown that industry-funded studies may differ in
terms of transparency and outcome reporting [25–27].
Finally, trials with an active comparator will be com-
pared to those with a placebo or ‘no treatment’ control
since trials with an active control arm may have meth-
odological differences, e.g. using a smaller target differ-
ence and thus requiring a larger sample size [28, 29].
This systematic review will be limited in that it relies pri-
marily on information from the trials’ results publication(s),
which may not be transparent about modification once the
study had begun and thus may not accurately reflect the a-
priori sample size calculation when the study was planned.
There is some evidence to suggest that practice is more
complex than trial reports suggest [30]. Nevertheless, the
reported sample size should reflect the final design and is
the natural one to assess, at least in the first instance.
The findings of this systematic review will provide evi-
dence on whether sufficient information is being reporting
in sample size calculations and explore variability in the
chosen sample size and reporting based on study design
features (including the justification of key inputs). This may
highlight areas for improvement in the reporting and
conduct of sample size calculations for hip and knee osteo-
arthritis trials, and to an extent, trials of other conditions.
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